Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: a retrospective observational study

BACKGROUND: Erenumab is a calcitonin gene-related peptide (CGRP)-receptor antibody inhibiting CGRP function. CGRP is prominently involved in the pathophysiology of migraine through nociceptive modulation in the trigeminovascular system. This study aims to explore the treatment effect of erenumab in...

Descripción completa

Detalles Bibliográficos
Autores principales: Dinh, Bui Bao Khanh, Aziz, Waseem Hamed, Terruzzi, Alessandro, Krieger, Derk Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670192/
https://www.ncbi.nlm.nih.gov/pubmed/34906111
http://dx.doi.org/10.1186/s12883-021-02507-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670192/
https://www.ncbi.nlm.nih.gov/pubmed/34906111
http://dx.doi.org/10.1186/s12883-021-02507-y

Ejemplares similares